In the current volatile market, shares of companies that boast strong fundamentals, like Regeneron Pharmaceuticals (REGN) and Michael Kors (KORS), will likely hold up well and are the top prospects for a stock watch list. Today’s Screen Of The Day is Top Fundamentals, highly rated companies with three-year sales and earnings growth rates of at least 25%. Here are five companies on the list that have seen both earnings and sales make robust gains
Regeneron Pharmaceuticals (REGN) says phase two-B testing for its dupilumab atopic dermatitis drug has been a success, setting up the drug for phase three testing this year. “While tonight’s news is clearly positive, we think it is more or less in line with investors’ expectations,” wrote Cowen analyst Phil Nadeau in a late Wednesday research note. Nadeau rates Regeneron stock as market perform, or hold. The drug is expected to treat moderate to
Regeneron Pharmaceuticals (REGN) rebounded more than 6% in afternoon trading on the stock market today when development partner Sanofi (SNY) said in a U.S. regulatory filing that it will raise its stake from 20.44% to 22.5%. The French drug giant’s move comes after Regeneron superstar Eylea, a treatment for age-related macular degeneration (AMD), received a European Medicines Agency endorsement on Friday to expand its use to other types of vision